Future prospects for breast cancer immunotherapy
Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1 (PD-1) receptor and its ligand 1 (PD-L1) or are di...
Main Authors: | V. F. Semiglazov, A. I. Tseluiko, R. V. Donskikh, P. V. Krivorotko, G. A. Dashyan, V. V. Semiglazov, A. V. Komyakhov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-11-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2740 |
Similar Items
-
The Immunotherapy Landscape in Adrenocortical Cancer
by: Guillaume J. Pegna, et al.
Published: (2021-05-01) -
Monocytes and cancer: promising role as a diagnostic marker and application in therapy
by: M. R. Patysheva, et al.
Published: (2019-05-01) -
Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
by: Haihui Jiang, et al.
Published: (2021-05-01) -
Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01) -
Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
by: Robert W. Wilkinson, et al.
Published: (2018-06-01)